Latest news with #GLP1agonists
The Sun
6 hours ago
- Health
- The Sun
The 3 natural alternatives to fat jabs weight loss doctor says can crush food cravings and keep you full for hours
WEIGHT loss jabs have soared in popularity in recent months, but while effective for some, aren't a one-size-fits-all solution. For those looking for a more natural route to weight loss, three easy, everyday meals that mimic some of the effects of GLP-1 agonists could be key to you shedding the pounds. More than a million Brits are thought to be on appetite-suppressing weight loss jabs. But according to weight loss doctor Professor Franklin Joseph, head of Dr Frank's Weight Loss Clinic, you don't always need a prescription to get a similar hunger-blunting effect. Certain everyday meals, when built with the right ingredients, can naturally slow digestion, steady blood sugar and send powerful 'fullness' signals to the brain, helping you stay full and beat the urge to snack. Prof Joseph recommends combining high protein, high fibre and healthy fats in the same dish. 'It's the magic trio for appetite control,' he said. 'You feel full sooner, stay full for longer and you avoid the sugar highs and crashes that drive cravings.' Why it works GLP-1 weight loss medications work by mimicking a natural gut hormone that slows stomach emptying and helps you feel satisfied after eating. But certain food combinations can create a similar effect without the needle. 'When you eat a meal rich in protein and fibre, you're naturally extending the time it takes to digest,' Prof Joseph explained. 'Add in healthy fats and you've got a triple lock on hunger. That's why these meals work for people on or off the medication.' Weight Loss Jabs - Pros vs Cons Three GLP-1 style meals to add to your week Protein-packed lentil and quinoa salad 4 A hearty mix of cooked lentils, quinoa, roasted vegetables and a lemon-tahini dressing. 'The plant protein from lentils and quinoa, plus fibre from the veg, keeps you going for hours,' Prof Joseph said. 'It's great as a main meal or batch-prepped for lunches.' Salmon and roasted veggie tray bake 4 Roast salmon alongside non-starchy vegetables like broccoli, peppers and courgette with a drizzle of olive oil. 'You get high-quality protein, omega-3 fats for satiety, and a big dose of fibre,' he said. 'This combination is incredibly filling but still low in calories per bite.' Greek yoghurt parfait with berries and nuts Layer unsweetened Greek yoghurt with mixed berries and a sprinkle of almonds or walnuts. 'It feels like a treat but ticks all the fullness boxes - protein from the yoghurt, fibre from the berries, healthy fats from the nuts,' Prof Joseph said. 'Perfect for breakfast or even dessert.' Prof Joseph added: 'The right plate can make all the difference. "You're not just eating less - you're eating smarter.' The 5 best exercises to lose weight By Lucy Gornall, personal trainer and health journalist EXERCISE can be intimidating and hard to devote yourself to. So how do you find the right workout for you? As a PT and fitness journalist, I've tried everything. I've taken part in endless fitness competitions, marathons and I maintain a regime of runs, strength training and Pilates. Fitness is so entrenched in my life, I stick to it even at Christmas! The key is finding an activity you love that can become a habit. My top five forms of exercise, especially if you're trying to lose weight, are: Walking Running Pilates High-intensity interval training (HIIT) Strength training
The Independent
14 hours ago
- Health
- The Independent
Millions of diabetes patients could be given weight loss jabs sooner
New draft guidance from Nice proposes a significant overhaul of type 2 diabetes care in England, moving towards personalised treatment to prevent serious complications. SGLT-2 inhibitors, which protect the heart and kidneys, are recommended as a first-line treatment option, potentially saving nearly 22,000 lives. The guidelines aim to address the current under-prescription of SGLT-2 inhibitors, particularly among women, older people, and black patients, to reduce health inequalities. GLP-1 receptor agonists, including semaglutide, are also suggested for earlier use in some patients, alongside tailored recommendations for specific conditions. This shift represents a holistic approach to type 2 diabetes management, focusing on cardiovascular and kidney health, and is open for public consultation until 2 October.
Reuters
07-08-2025
- Business
- Reuters
Lilly raises full-year earnings forecasts on surging demand for weight-loss drug
Aug 7 (Reuters) - Eli Lilly (LLY.N), opens new tab raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk's ( opens new tab Wegovy. However, shares of the U.S. drugmaker fell over 10% to $671.54 in premarket trading after data from its oral weight loss drug, orforglipron, disappointed investors. Orforglipron helped patients lose 12.4% of their weight on average after 72 weeks, less than the 14.9% weight loss seen in a previous trial of Novo's Wegovy over 68 weeks and below what analysts were expecting. Lilly competes with Danish drugmaker Novo Nordisk ( opens new tab in the fast-growing market for weight-loss drugs known as GLP-1 agonists. These drugs are expected to bring in $150 billion in industry-wide revenue over the next decade. Novo said on Wednesday that it expects continued competition from copycat versions of its blockbuster obesity drug this year and could face layoffs as it battles rising pressure from its main U.S. rival Lilly. Weekly U.S. prescriptions were at 418,597 for Zepbound and at 281,725 for Wegovy for the week ended July 25, according to IQVIA data provided by analysts. Lilly said its share of the U.S. market for incretins, the class of drugs to which diabetes drug Mounjaro and weight-loss drug Zepbound belong, increased to 57% during the quarter. Sales of Mounjaro came in at $5.20 billion for the second quarter, compared with analysts' expectations of $4.74 billion, according to data compiled by LSEG. Zepbound clocked in sales of $3.38 billion for the quarter. Analysts were expecting sales of $2.95 billion. The company now expects to earn $21.75 to $23 per share on an adjusted basis this year, compared with its previous forecast for a profit of $20.78 to $22.28 per share. The U.S. drugmaker now expects annual sales of $60 billion to $62 billion, compared with its previous forecast of $58 billion and $61 billion. Analysts were expecting revenue of about $60 billion and profit of $21.74 per share for 2025.
Yahoo
07-08-2025
- Business
- Yahoo
Eli Lilly raises full-year profit forecast on weight-loss drug strength
(Reuters) -Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk's Wegovy. However, shares of the U.S. drugmaker fell about 12% in premarket trading after it reported data from its oral weight loss drug, orforglipron, earlier in the day. Orforglipron helped patients lose 12.4% of their weight on average after 72 weeks. At least three analysts said the market had been looking for orforglipron to match Wegovy's 14.9% weight loss over 68 weeks, as shown in a 2021 trial, with some expecting the pill to surpass Novo's popular drug. Lilly competes with Danish drugmaker Novo Nordisk in the fast-growing market for weight-loss drugs known as GLP-1 agonists, which is expected to top $150 billion in revenue over the next decade. Last week, Novo cut its profit forecast for the second time this year, citing lower-than-expected U.S. growth and competition from cheaper copies of Wegovy made by compounding pharmacies. The company now expects to earn $21.75 to $23 per share on an adjusted basis this year, compared with its previous forecast for a profit of $20.78 to $22.28 per share. Analysts were expecting a profit of $21.74 per share for 2025, according to data compiled by LSEG. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Reuters
07-08-2025
- Business
- Reuters
Eli Lilly raises full-year profit forecast on weight-loss drug strength
Aug 7 (Reuters) - Eli Lilly (LLY.N), opens new tab raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk's ( opens new tab Wegovy. However, shares of the U.S. drugmaker fell about 12% in premarket trading after it reported data from its oral weight loss drug, orforglipron, earlier in the day. Orforglipron helped patients lose 12.4% of their weight on average after 72 weeks. At least three analysts said the market had been looking for orforglipron to match Wegovy's 14.9% weight loss over 68 weeks, as shown in a 2021 trial, with some expecting the pill to surpass Novo's popular drug. Lilly competes with Danish drugmaker Novo Nordisk ( opens new tab in the fast-growing market for weight-loss drugs known as GLP-1 agonists, which is expected to top $150 billion in revenue over the next decade. Last week, Novo cut its profit forecast for the second time this year, citing lower-than-expected U.S. growth and competition from cheaper copies of Wegovy made by compounding pharmacies. The company now expects to earn $21.75 to $23 per share on an adjusted basis this year, compared with its previous forecast for a profit of $20.78 to $22.28 per share. Analysts were expecting a profit of $21.74 per share for 2025, according to data compiled by LSEG.
